Carbon fiber recovery compositions and methods

US10611892B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10611892-B2
Application numberUS-201715482012-A
CountryUS
Kind codeB2
Filing dateApr 7, 2017
Priority dateApr 7, 2017
Publication dateApr 7, 2020
Grant dateApr 7, 2020

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Methods and compositions for depolymerizing the polymer component of fiber reinforced polymers to facilitate the recovery of free fibers.

First claim

Opening claim text (preview).

What is claimed is: 1. A method for recovering free fibers from a fiber reinforced polymer comprising: admixing the fiber reinforced polymer with a depolymerization composition comprising an ionic salt and a protective compound that protects the ionic salt from degradation to form a recycle admixture; and heating the recycle admixture to a processing temperature at which the protective compound is molten and at which the ionic salt dissolves in the protective compound and maintaining the recycle admixture at the processing temperature for a period of time sufficient to at least partially depolymerize a portion of the fiber reinforced polymer to yield free fiber and decomposed polymer. 2. The method of claim 1 wherein the ionic salt is liquid in the depolymerization composition at a temperature below 200° C. 3. The method of claim 1 wherein the ionic salt contains at least one of C, H, N, and P. 4. The method of claim 1 wherein the ionic salt includes one or more of a phosphonium ion, ammonium ion, hexafluorophosphate ion, imidazolium ion, pyrrolidinium ion, pyridinium ion, imide on, sulfonate ion, and a trifluoromethane sulfonyl imide (TFSI) ion. 5. The method of claim 1 wherein the ionic salt includes a phosphonium ion. 6. The method of claim 1 wherein the ionic salt includes at least one phenyl group. 7. The method of claim 1 wherein the ionic salt is one or more of 3-[2-(4-nitro-phenyl)-2-oxoethyl]-1-methylimidazolium (C 12 H 14 N 3 O 2 ); 3-[2-(3-chlorophenyl)-2-oxoethyl]-1-methylimidazolium (C 12 H 12 ClN 2 O); 3-[2-(4-chlorophenyl)-2-oxoethyl]-1-methylimidazolium (C 12 H 12 ClN 2 O); 1-ethyloxy-3-[4-nitrobenzyl] imidazolium (C 12 H 14 N 3 O 3 ); 1-methyloxy-3-[2-(4-chlorophenyl)-2-oxoethyl]imidazolium (C 12 H 12 ClN 2 O 2 ); 3-[2-(4-nitro-phenyl)-2-oxoethyl]-1-methylimidazolium (C 12 H 12 NO 3 ); 1-etheneoxy-3-[2,4-dichlorobenzyl] imidazolium (C 12 H 11 Cl 2 N 2 O); 1-ethyloxy-3-[2,4-dichlorobenzyl] imidazolium (C 12 H 13 C 12 N 2 O); 3-[2-(3,4-dichlorophenyl)-2-oxoethyl]-1-methylimidazolium (C 12 H 11 Cl 2 N 2 O); 1-hydrocinnamyl-3-methyl imidazolium (C 13 H 17 N 2 ); 1-nonyl-3-methylimidazolium (C 13 H 25 N 2 ); I-octyl-3-ethylimidazolium (C 13 H 25 N 2 ); 1,3-di-(1-butoxymethyl)-imidazolium (C 13 H 25 N 2 O 2 ); 1-Methyl-3-(2-oxo-2-o-tolyl-ethyl)-imidazolium (C 13 H 15 N 2 O); 1-(4-methoxynbutyl)-3-methylimidazolium (C 9 H 17 N 2 O); 1-[2-(2-methoxyethoxy)ethyl]-3-methyl imidazolium (C 9 H 17 N 2 O 2 ); 1,3-dibenzylimidazolium (C 10 H 10 N 2 ); 1-hexyl-3-methylimidazolium (C 10 H 19 N 2 ); 1-[2-phenyl-2-oxyethyl]-3-methyl imidazolium (C 10 H 11 N 2 O); 1-(3-cyano-propyl)-3-(2-cyano-ethyl)imidazolium (C 10 H 13 N 4 ); 1-(2-furan-2-yl-2-oxo-ethyl)-3-methylimidazolium (C 10 H 11 N 2 O 2 ); 1-hydroxy-3-[2,4-dichlorobenzyl]imidazolium (C 10 H 9 C 12 N 2 O); 1-benzyl-3-methylimidazolium (C 11 H 13 N 2 ); 1-benzyl-3-methylimidazolium (C 11 H 13 N 2 ); 1-heptyl-3-methylimidazolium (C 11 H 21 N 2 ); 1-hexyl-3-ethylimidazolium (C 11 H 21 N 2 ), 1,3-dibutylimidazolium (C 11 H 21 N 2 ), 1-(4-methoxyphenyl)-3-methylimidazolium (C 11 H 13 ON 2 ); phenyl-3-methylimidazolium (C 12 H 15 N 2 ); 1-methyl-3-(3-methyl-benzyl)-imidazolium (C 12 H 15 N 2 ); 1-methyl-3-(2-methyl-benzyl)-imidazolium (C 12 H 15 N 2 ); 3-[2-(4-bromo-phenyl)-2-oxoethyl]-1-methyl imidazolium (C 12 H 12 BrN 2 O); 1-octyl-3-methylimidazolium (C 12 H 23 N 2 ); phenylethanoyl-3-propylimidazolium (C 12 H 15 N 2 O); heptoxymethyl-3-methylimidazolium (C 12 H 23 N 2 O); 3-[2-(2-florophenyl)-2-oxoethyl]-1-methyl imidazolium (C 12 H 12 FN 2 O); 11-(1-propoxymethyl)-3-(1-butoxymethyl) imidazolium (C 12 H 23 N 2 O 2 ); 3-(4-Cyano-benzoyl)-1-methyl imidazolium (C 13 H 12 N 3 O); 3-[2-(4-methyloxyphenyl)-2-oxoethyl]-1-methyl imidazolium (C 13 H 15 N 2 O 2 ); 3-[2-(2-methyloxyphenyl)-2-oxoethyl]-1-methylimidazolium (C 13 H 15 N 2 O 2 ); 1-ethyloxy-3-[2-(4-chlorophenyl)-2-oxoethyl]imidazolium (C 13 H 14 ClN 2 O 2 ); 1-hydroxy-3-(3,4,5-trimethyloxybenzyl)imidazolium (C 13 H 17 N 2 O 4 ); 1-ethyl-3-[2-(4-bromo-phenyl)-2-oxoethyl]imidazolium (C 13 H 14 BrN 2 O); 1-methyl-3-[2,6-(S)-dimethylocten-2-yl]imidazolium (C 14 H 25 N 2 ); 1-octyl-3-propylimidazolium (C 14 H 27 N 2 ); 1-decyl-3-methylimidazolium (C 14 H 27 N 2 ); 3-[2-(1,2-dimethyloxyphenyl)-2-oxoethyl]-1-methylimidazolium (C 14 H 17 N 2 O); 3-(1,1-dimethyl-2-phenyl-2-oxoethyl)-1-methylimidazolium (C 14 H 17 N 2 O); 3-[2-(3,5-dimethoxylphenyl)-2-oxoethyl]-1-methylimidazolium (C 14 H 17 N 2 O 3 ); 3-[2-(3,4-dimethyloxyphenyl)-2-oxoethyl]-1-methylimidazolium (C 14 H 17 N 2 O); 1-(1-nonoxymethyl)-3-methylimidazolium (C 14 H 27 N 2 O); 3-[2-(3-ethoxylphenyl)-2-oxoethyl]-1-methylimidazolium (C 14 H 17 N 2 O 2 ); 3-[2-(4-ethoxylphenyl)-2-oxoethyl]-1-methylimidazolium (C 14 H 17 N 2 O 2 ); 1-(1-amyloxymethyl)-3-butoxymethyl imidazolium (C 14 H 17 N 2 O 2 ); 1-amyl-3-benzylimidazolium (C 15 H 21 N 2 ); 1-(1-hexyloxymethyl)-3-(1-butoxymethyl) imidazolium (C 15 H 29 N 2 O 2 ); 1-undecyl-3-methylimidazolium (C 15 H 29 N 2 ); 1-(1-decyloxymethyl)-3-methylimidazolium (C 15 H 29 N 2 O); 3-[2-(3-propyloxylphenyl)-2-oxoethyl]-1-methyl imidazolium (C 15 H 19 N 2 O 2 ); 3-[2-(3-methyloxylphenyl)-2-oxoethyl]-1-isopropylimidazolium (C 15 H 19 N 2 O 2 ); 3-[2-(2,4,6-trimethyloxyphenyl)-2-oxoethyl]-1-methylimidazolium (C 15 H 19 N 2 O 2 ); 3-[2-α-naphthyl-2-oxoethyl]-1-methylimidazolium (C 16 H 15 N 2 O); 1-(1-heptyloxymethyl)-3-(1-butoxymethyl) imidazolium) imidazolium (C 16 H 31 N 2 O 2 ); 1-dodecyl-3-methylimidazolium (C 16 H 31 N 2 ); 1-(1-undecyloxymethyl)-3-methylimidazolium (C 16 H 31 N 2 O); dimethylpropionyloxy)-3-[2-(4-chlorophenyl)-2-oxoethyl]imidazolium (C 16 H 18 ClN 2 O 3 ); 1-(1-dodecyloxymethyl)-3-methylimidazolium (C 17 H 33 N 2 O); 1-tridecyl-3-methylimidazolium (C 17 H 33 N 2 ); 1-benzyloxy-3-(2,4-dichlorobenzyl)imidazolium (C 17 H 15 C 12 N 2 O); 1-(4-benzoyl-benzyl)-3-methyl-imidazolium (C 18 H 17 N 2 O); 1-tetradecyl-3-methylimidazolium (C 18 H 35 N 2 ); 3-[2-(3-methyloxylphenyl)-2-oxoethyl]-1-phenylimidazolium (C 18 H 17 N 2 O 2 ); 1-(1-nonyloxymethyl)-3-(1-butoxymethyl)imidazolium (C 18 H 35 N 2 O 2 ); 1-(2-phenylethyloxy)-3-(2,5-dichlorobenzyl)imidazolium (C 18 H 17 C 12 N 2 O); 1-[2,4-dichlorophenylmethyloxyl]-3-[2-(4-chlorophenyl)-2-oxoethyl]imidazolium (C 18 H 14 C 13 N 2 O); 1-pentadecyl-3-methylimidazolium (C 19 H 37 N 2 ); 1-phenyloxy-3-[2-(4-dimethylamino-phenyl)-2-oxoethyl]imidazolium (C 19 H 20 N 3 O 2 ); 1-(1-decyloxymethyl)-3-(1-butoxy methyl)imidazolium (C 19 H 37 N 2 O 2 ); 1-hexadecyl-3-methylimidazolium (C 20 H 39 N 2 ); 1-(1-decyloxymethyl)-3-hexyl imidazolium (C 20 H 39 N 2 O); 1-(1-undecyloxymethyl)-3-(1-butoxy methyl)imidazolium (C 20 H 39 N 2 O); 1-(1-undecyloxymethyl)-3-hexyl imidazolium (C 21 H 41 N 2 O); 1-octadecyl-3-methylimidazolium (C 22 H 43 N 2 ); 1-cosyl-3-methylimidazolium (C 24 H 47 N 2 ); 1-(2-(2-(2-(2-(2-(2-(2-(methacryloyloxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)-3-ethylimidazolium (C 25 H 45 O 9 N 2 ); polymer of PEOimidazolium; 3-dihydroxy-2-bromoimidazolium (C 3 H 4 BrN 2 O 2 ); 1,3-dimethyl 5 chloroimidazolium (C 5 H 8 ClN); 2,4,5-trimethylimidazolium (C 6 H 11 N 2 ); 1,2,3-trimethylimidazolium (C 6 H 11 N 2 ); 1,3-dimethyl-nimtrimleimidazolium (C 6 H 8 N 3 S); 1,2-dimethyl-3-ethylimidazolium (C 7 H 13 N 2 ); 1-ethyl-3,5-dimethylimidazolium (C 7 H 13 N 2 ); 1-ethyl-2,3-dimethylimidazolium (C 7 H 13 N 2 ), 1,3-dimethyl-4-methylimidazolium (C 8 H 15 N 2 ); 1,2-methyl-3-propylimidazolium (C 8 H 15 N 2 ); 1,2-ethyl-3-methylimidazolium (C 8 H 15 N 2 ); 1-propyl-2,3-dimethylimidazolium (C 8 H 15 N 2 ); 1-butyl-2,3-dimethylimidazolium (C 9 H 17 N 2 ); 3-butyl-1-,5-dimethylimidazolium (C 9 H 17 N 2 ); 1,3-dimethyl-2-phenylimidazolium (C 11 H 13 N 2 ); 1-benzyl-2-methyl-3-propyl (C 13 H 19 N 2 ), 1-octyl-2,3-dimethylimidazolium (C 13 H 25 N 2 ); 1,3-dipr

Assignees

Inventors

Classifications

  • by treatment with organic material · CPC title

  • Salts thereof · CPC title

  • Carbon filaments; Apparatus specially adapted for the manufacture thereof · CPC title

  • C08J11/00Primary

    Recovery or working-up of waste materials (recovery of plastics B29B17/00; polymerisation processes involving purification or recycling of waste polymers or their depolymerisation products C08B, C08C, C08F, C08G, C08H) · CPC title

  • Elements · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10611892B2 cover?
Methods and compositions for depolymerizing the polymer component of fiber reinforced polymers to facilitate the recovery of free fibers.
Who is the assignee on this patent?
Boeing Co
What technology area does this patent fall under?
Primary CPC classification C08J11/00. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Apr 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).